Pharmaceutical News

RSS

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.

9 Oct 2015

Study: Women less likely than men to have good relief of chronic pain with long-term opioid use

Women, and especially younger women, are much less likely than men to have good relief of chronic, non-cancer pain with long-term opioid use, with only one in five women reporting low levels of pain and high levels of function with chronic opioid therapy in a new study published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

9 Oct 2015

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

9 Oct 2015

$Anti-osteoporotic therapy can decrease subsequent fracture risks by 40%: Study$

Anti-osteoporotic therapy can decrease subsequent fracture risks by 40%: Study

Osteoporosis, a disease of progressive bone loss, affects 70 percent of the U.S. population older than age 50: one in two women--and one in five men. These individuals are at risk for fragility fractures, a break that results from a fall, or occurs in the absence of obvious trauma, and most commonly seen in the wrist, the upper arm, the hip, and the spine.

9 Oct 2015

Research on investigational menopause drug wins first prize

Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, today announced it received top honors for its research on investigational drug lasofoxifene at the 26th annual North American Menopause Society (NAMS) meeting in Las Vegas last week.

9 Oct 2015

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Salix Pharmaceuticals and Pharming Group NV announced today that the U.S. Food and Drug Administration has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor [recombinant]) 50 IU/kg.

8 Oct 2015

FDA grants Breakthrough Therapy Designation to Lilly's abemaciclib for treatment of metastatic breast cancer

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer.

8 Oct 2015

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan plc today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San Diego.

8 Oct 2015

Immune-molecule-based mop-up therapy reduces specific type of breast tumor in mice

Disabling a cancer-causing pathway and administering an immune-molecule-based mop-up therapy eradicated a specific type of breast tumor in mice, according to researchers in the Perelman School of Medicine at the University of Pennsylvania.

8 Oct 2015

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.

7 Oct 2015

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC). It is an option when certain changes in the cancer cells (anaplastic lymphoma kinase-positive) stimulate tumour growth and patients have already been pretreated with crizotinib.

7 Oct 2015

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Immune Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug Application in the U.S. to expand recruiting for its first in class lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP).

7 Oct 2015

Solix Algredients introduces Solasta Astaxanthin to B2B marketplace

Solix Algredients, Inc. has introduced Solasta Astaxanthin to the B2B ingredients marketplace. Solasta is a natural astaxanthin extract produced from the microalga Haematococcus pluvialis, the richest natural source of the antioxidant. Research has shown that algal astaxanthin has superior antioxidant activity compared to other well-known antioxidants.

7 Oct 2015

Influenza-related pneumonia hospitalizations could be prevented through influenza vaccination

More than half of hospitalizations due to influenza pneumonia could be prevented by influenza vaccination, according to a study led by investigators at Vanderbilt University Medical Center, published this week in the Journal of the American Medical Association.

7 Oct 2015

Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation to TXA127 (angiotensin 1-7) to reduce skeletal muscle damage and fibrosis and thereby improve muscle strength in Duchenne Muscular Dystrophy (DMD) patients.

6 Oct 2015

Acetaminophen Awareness Coalition issues safety message to consumers about flu medicines

With cold and flu season around the corner, consumers will soon begin to purchase medicines such as cough syrup, throat lozenges, and nasal sprays to help get relief from symptoms such as fever, coughs, congestion, and more. Many of the medicines used to treat these cold and flu symptoms can contain common drug ingredients such as acetaminophen.

6 Oct 2015

Flu vaccine significantly reduces stroke risk

The risk of suffering a stroke is significantly reduced for up to two months after receiving a flu vaccine, a major new study has shown.

6 Oct 2015

Benzodiazepines heighten risks for dementia and death

Patients taking benzodiazepines to treat psychiatric conditions should consider transitioning to other therapies because of heightened risks for dementia and death, according to clinicians from the American College of Osteopathic Neurologists and Psychiatrists.

6 Oct 2015

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

A new population-based study from The University of Texas Medical Branch at Galveston showed for the first time that exposure to testosterone therapy over a five-year period was not associated with an increased risk of aggressive prostate cancer. Further, risk of high-grade prostate cancer did not increase according to the total number of testosterone injections.

5 Oct 2015

Tris Pharma announces launch of generic TUSSIONEX

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced the launch of Tris-labeled generic TUSSIONEX, an extended-release suspension containing hydrocodone polistirex and chlorpheniramine polistirex.

1 Oct 2015

Pharmaceutical News

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Study: Women less likely than men to have good relief of chronic pain with long-term opioid use

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

Anti-osteoporotic therapy can decrease subsequent fracture risks by 40%: Study

Research on investigational menopause drug wins first prize

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

FDA grants Breakthrough Therapy Designation to Lilly's abemaciclib for treatment of metastatic breast cancer

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Immune-molecule-based mop-up therapy reduces specific type of breast tumor in mice

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Solix Algredients introduces Solasta Astaxanthin to B2B marketplace

Influenza-related pneumonia hospitalizations could be prevented through influenza vaccination

Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

Acetaminophen Awareness Coalition issues safety message to consumers about flu medicines

Flu vaccine significantly reduces stroke risk

Benzodiazepines heighten risks for dementia and death

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

Tris Pharma announces launch of generic TUSSIONEX

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News